A 55-year-old woman with cirrhosis and ascites develops hyponatremia (Na+ 125 mEq/L) without neurological symptoms. Regarding the pathophysiology and management of hyponatremia in cirrhosis, all of the following statements are true EXCEPT:

Explanation

## Hyponatremia in Cirrhosis: Pathophysiology and Management **Key Point:** Hyponatremia in advanced cirrhosis is a marker of severe liver disease and portal hypertension, driven by SIADH-like physiology. Vaptans are NOT contraindicated and are increasingly used in selected cases. ### Pathophysiology in Cirrhosis | Feature | Mechanism | |---------|----------| | **Primary defect** | Impaired renal free water excretion (SIADH-like) | | **Trigger** | Splanchnic vasodilation → decreased effective circulating volume | | **ADH response** | Inappropriate ADH secretion despite hypo-osmolality | | **Aquaporin-2** | Increased expression in collecting duct → water reabsorption | **High-Yield:** Hyponatremia in cirrhosis is **NOT dilutional** in the sense of simple hypervolemia; it reflects **selective impairment of free water excretion** in the setting of portal hypertension and splanchnic vasodilation. ### Management Algorithm ```mermaid flowchart TD A[Hyponatremia in Cirrhosis]:::outcome --> B{Symptomatic?}:::decision B -->|Yes| C[Hypertonic saline]:::action B -->|No| D[Asymptomatic/chronic]:::outcome D --> E[Fluid restriction 800-1000 mL/day]:::action E --> F{Response adequate?}:::decision F -->|Yes| G[Continue restriction]:::action F -->|No| H[Consider vaptans]:::action H --> I[Tolvaptan or vaptans]:::outcome ``` ### Why Option 2 is Wrong **Vaptans are NOT contraindicated in cirrhosis.** In fact, they are increasingly used in clinical practice for hyponatremia refractory to fluid restriction. While vaptans carry theoretical risk of worsening renal perfusion in the setting of severe liver disease, they do not universally precipitate hepatorenal syndrome and are considered a reasonable option when fluid restriction fails. **Clinical Pearl:** Vaptans (tolvaptan, conivaptan) block V2-ADH receptors in the collecting duct, promoting free water excretion (aquaresis). In cirrhosis, they can improve serum sodium without worsening ascites, making them useful for refractory hyponatremia. **Warning:** Do not confuse "relative caution in severe liver disease" with "absolute contraindication." Vaptans require careful monitoring of sodium levels and renal function, but they are not contraindicated outright.